Komori
Earnings presentation materials3649FINDEX Inc.Information and Communications, Services and Others

Supplementary Financial Results Briefing Materials for the Third Quarter of the Fiscal Year Ending December 2026

Cumulative results for the third quarter of the fiscal year ending December 2026 showed declines in both revenue and profit, but the healthcare business offset the decline in the public-sector business and delays in health tech. The Company assessed progress toward its full-year plan as on schedule. The full-year earnings forecast was left unchanged.

Worth reading
77Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
-17.5
Operating profit YoY (%)
Wording
Conditional
How definitive the wording is.

Contents of this document

Supplementary materials to the earnings summaryThird quarter of the fiscal year ending December 202614 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥4,297 million-1.7%
Operating profit¥985 million-17.5%
Ordinary income¥1,034 million-16.6%
Net income¥639 million-25.1%
Selling, general and administrative expenses¥1,769 million
Gross Profit MarginEquivalent to 64.1% (gross profit of ¥2,755 million, down 2.0% year on year)
Operating profit margin22.9% (year-on-year comparison Not disclosed)
Results for the three months of the current quarterThe quarterly revenue, orders received and order backlog trends include standalone Q3 figures. Standalone Q3 figures for profit and loss items were Not disclosed
Full-year earnings forecast
Net Sales
¥6,209 million
Operating profit
¥1,829 million
Ordinary income
¥1,889 million
Profit attributable to owners of the parent
¥1,302 million
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales69.2%
Operating profit53.9%
Ordinary income54.8%
Profit attributable to owners of the parent49.1%
Medical business revenue72.8%
Public business revenue63.5%
Healthtech business revenue19.0%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Overall progress is on schedule
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Year-on-year operating income varianceDown from ¥1,300 million in Q1-3FY2025 to ¥985 million in Q1-3FY2026
Revenue factors-¥48 million
Gross margin factorsOperating loss of ¥9 million
Selling, general and administrative expense factor△¥152 million
By segmentHealthcare: △¥112 million, public sector: △¥71 million, health tech: △¥26 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Revenue and profit are seasonal, concentrated in Q1 and Q4. Numerical assumptions for foreign exchange rates, raw material prices and other factors were Not disclosed
New initiatives
  • The medical data platform business is scheduled to begin operations at the start of the next fiscal year
  • Established an operations center for the medical data business in Tokyo
  • Started shipments of GAP to Thailand and is expanding sales in the ASEAN region
  • Upfront investment in hiring specialized personnel, ERP renewal and cybersecurity measures
Key KPIsA metric the company considers important as a management benchmark.
  • Share of recurring revenue in the Medical segment35.9 %
    Year on year against the same period last yearUp from 33.2% in the previous year
  • Total DocuMaker Office users49,918 people
  • Number of facilities using medical systems2,292 Facility
  • Total number of public-sector system customers82 Facility
  • Penetration at the main hospitals of Japanese university hospitals80 %
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Average number of packages per facility: large hospitals 4.77, medium-sized hospitals 3.09, small hospitals 2.32, clinics 2.72
Segment results
  • Healthcare business
    Net Sales¥3,967 million (YoY -1.2%)
    Operating profit¥1,106 million (YoY -9.2%)
  • Public-sector business
    Net Sales¥265 million (YoY -10.0%)
    Operating profit¥42 million (YoY -62.9%)
  • Healthtech business
    Net Sales¥64 million (YoY +4.5%)
    Operating profit¥-162 million
Medium-term management plan targets
2030 plan: revenue of ¥8,520 million, operating profit of ¥3,220 million, EPS of ¥96.3 and annual dividend of ¥48
Financial targets
Dividend payout ratio of 50%, DOE floor of 8.5%, and maintenance and improvement of ROE
Market Size / Share
Medical, healthcare and pharmaceutical DX markets; domestic TAM, SAM and SOM for document management systems of approximately ¥74 billion, ¥40 billion and ¥5.5 billion, respectively; global market for perimeter measurement devices of approximately ¥50 billion and domestic market of approximately ¥2.1 billion; adoption rate at the headquarters of domestic university hospitals of approximately 80%
Orders received and order backlog
Quarterly trends are provided. The amounts of Q3 orders received and order backlog are shown only in the graph, and clear figures are Not disclosed in the body text
Annual Dividend
Forecast for the fiscal year ending December 2026
Interim13
End of period14
Annual27
Payout ratio
50.0% (forecast for the fiscal year ending December 2026)
Acquisition of treasury shares
The graph shows share buybacks, but the amount, number of shares and period of the acquisition program were Not disclosed
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings summary
Fiscal Period CoveredThird quarter of the fiscal year ending December 2026
Net Sales¥4,297 million (YoY -1.7%)
Operating profit¥985 million (YoY -17.5%)
Ordinary income¥1,034 million (YoY -16.6%)
Net income¥639 million (YoY -25.1%)
Gross Profit MarginEquivalent to 64.1% (gross profit of ¥2,755 million, down 2.0% year on year)
Operating profit margin22.9% (year-on-year comparison Not disclosed)
Selling, general and administrative expenses¥1,769 million
Results for the three months of the current quarterThe quarterly revenue, orders received and order backlog trends include standalone Q3 figures. Standalone Q3 figures for profit and loss items were Not disclosed
Full-year earnings forecastNet Sales ¥6,209 million / Operating profit ¥1,829 million / Ordinary income ¥1,889 million / Profit attributable to owners of the parent ¥1,302 million
Progress against full-year forecastNet Sales 69.2% / Operating profit 53.9% / Ordinary income 54.8% / Profit attributable to owners of the parent 49.1% / Medical business revenue 72.8% / Public business revenue 63.5% / Healthtech business revenue 19.0%
Self-assessment against the planOverall progress is on schedule
Segment resultsSegment Healthcare business / Net Sales ¥3,967 million (YoY -1.2%) / Operating profit ¥1,106 million (YoY -9.2%), Segment Public-sector business / Net Sales ¥265 million (YoY -10.0%) / Operating profit ¥42 million (YoY -62.9%), Segment Healthtech business / Net Sales ¥64 million (YoY +4.5%) / Operating profit ¥-162 million
Breakdown of Factors Affecting the ChangeYear-on-year operating income variance Down from ¥1,300 million in Q1-3FY2025 to ¥985 million in Q1-3FY2026 / Revenue factors -¥48 million / Gross margin factors Operating loss of ¥9 million / Selling, general and administrative expense factor △¥152 million / By segment Healthcare: △¥112 million, public sector: △¥71 million, health tech: △¥26 million
Key KPIsIndicator Share of recurring revenue in the Medical segment / Value 35.9 % / Year on year against the same period last year Up from 33.2% in the previous year, Indicator Total DocuMaker Office users / Value 49,918 people / Year on year against the same period last year Not disclosed, Indicator Number of facilities using medical systems / Value 2,292 Facility / Year on year against the same period last year Not disclosed, Indicator Total number of public-sector system customers / Value 82 Facility / Year on year against the same period last year Not disclosed, Indicator Penetration at the main hospitals of Japanese university hospitals / Value 80 % / Year on year against the same period last year Not disclosed
Unit price and quantity metricsAverage number of packages per facility: large hospitals 4.77, medium-sized hospitals 3.09, small hospitals 2.32, clinics 2.72
Assumptions Underlying the Business OutlookRevenue and profit are seasonal, concentrated in Q1 and Q4. Numerical assumptions for foreign exchange rates, raw material prices and other factors were Not disclosed
Medium-term management plan targets2030 plan: revenue of ¥8,520 million, operating profit of ¥3,220 million, EPS of ¥96.3 and annual dividend of ¥48
Financial targetsDividend payout ratio of 50%, DOE floor of 8.5%, and maintenance and improvement of ROE
Annual DividendForecast for the fiscal year ending December 2026 Interim 13 / End of period 14 / Annual 27
Payout ratio50.0% (forecast for the fiscal year ending December 2026)
Acquisition of treasury sharesThe graph shows share buybacks, but the amount, number of shares and period of the acquisition program were Not disclosed
Orders received and order backlogQuarterly trends are provided. The amounts of Q3 orders received and order backlog are shown only in the graph, and clear figures are Not disclosed in the body text
Market Size / ShareMedical, healthcare and pharmaceutical DX markets; domestic TAM, SAM and SOM for document management systems of approximately ¥74 billion, ¥40 billion and ¥5.5 billion, respectively; global market for perimeter measurement devices of approximately ¥50 billion and domestic market of approximately ¥2.1 billion; adoption rate at the headquarters of domestic university hospitals of approximately 80%
New initiativesThe medical data platform business is scheduled to begin operations at the start of the next fiscal year, Established an operations center for the medical data business in Tokyo, Started shipments of GAP to Thailand and is expanding sales in the ASEAN region, Upfront investment in hiring specialized personnel, ERP renewal and cybersecurity measures
Items this document does not state (5)
Number of stores and locationsNumber of employeesRisk amount incorporated into the outlookCapital expendituresKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Selling, general and administrative expenses increased due to upfront investment in personnel costs, the renewal of the in-house ERP system, and infrastructure and security enhancements. The public-sector business was affected by the reaction to a large project in the previous fiscal year, while health tech was affected by the failure to meet the GAP sales plan and delays in the launch of the medical data platform. The healthcare business, however, drove overall performance.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Financial Results Briefing Materials for the Third Quarter of the Fiscal Year Ending December 2026 | FINDEX Inc. (3649) timely disclosure | Komori